[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508122":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":54,"collaborators":27,"id":58,"slug":27,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":27,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":27,"enrollmentInfo":66,"targetDuration":27,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":40,"whyStopped":27,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"kisspeptin pump","EXPERIMENTAL","SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes); administration of a single shot of leuprolide acetate (previously GnRH was used in this study)",[13,14],"Drug: kisspeptin 112-121","Drug: leuprolide acetate",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","kisspeptin 112-121","SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)",[9],[22],"metastin 45-54",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"leuprolide acetate","Single SC bolus",[9],null,[29],{"name":30,"affiliation":5,"role":31},"Stephanie Seminara, MD","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":27,"email":37},"Study Coordinator","CONTACT","617-726-1895","MGHKisspeptinResearch@partners.org",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-71.05977,42.35843,{"lat":50,"lon":49},[53],{"name":34,"role":35,"phone":36,"phoneExt":27,"email":37},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"SPONSOR_INVESTIGATOR","Stephanie B. Seminara, MD","Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine","100508122",false,"NCT05896293","Kisspeptin Administration Subcutaneously to Patients With IHH","Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders","Inclusion Criteria:\n\n* Congenital IHH\n\n  o Confirmed diagnosis by medical provider supported by low sex steroids in the setting of low or inappropriately normal gonadotropins\n* Normal blood pressure (systolic BP \\\u003C 140 mm Hg, diastolic \\\u003C 90 mm Hg)\n* No current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and method of administration\n\nExclusion Criteria:\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol\n* Excessive alcohol consumption (\\>10 drinks\u002Fweek) and\u002For active use of illicit drugs\n\n  o Any active use of marijuana will be evaluated by a study medical professional to determine if it may impact study participation.\n* Pregnant or trying to become pregnant\n* Breast feeding\n* History of: bilateral oophorectomy (both ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding","ALL","18 Years",{"count":67,"type":68},36,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time.\n\nFunding Source: FDA OOPD",[74],"Hypogonadotropic Hypogonadism",[74,76,77],"Kisspeptin","Idiopathic Hypogonadotropic Hypogonadism","2025-09-30",{"date":80,"type":81},"2025-10-03","ACTUAL",{"date":83,"type":81},"2023-02-03",{"date":85,"type":68},"2028-05",{"name":56,"class":6},1]